Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Hackensack Meridian Health
Acerta Pharma BV
Sana Biotechnology
City of Hope Medical Center
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
Sana Biotechnology
Jonsson Comprehensive Cancer Center
City of Hope Medical Center
City of Hope Medical Center
Synthekine
Bio-Path Holdings, Inc.
Nkarta, Inc.